Tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor and daily living activities in early-stage Parkinson’s disease compared with placebo over 26 weeks.
Flexible dosing (5-15 mg once daily) was generally well tolerated, with adverse events mostly mild-to-moderate and manageable; nausea, headache, and dizziness were the most common effects.
The trial showed low incidences of somnolence and impulse control disorders, differentiating tavapadon from traditional D2/D3 agonists.
Long-term safety and efficacy remain to be established in ongoing extension studies.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
